Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer

ABSTRACT IMscin001 is a two‐part dose‐finding (Phase Ib) and ‐confirmation (Phase III) study to evaluate atezolizumab pharmacokinetics of subcutaneous (SC) compared with intravenous (IV) administration in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC). The objectives...

Full description

Saved in:

Bibliographic Details
Published in:	CPT: pharmacometrics and systems pharmacology Vol. 14; no. 4; pp. 726 - 737
Main Authors:	Chan, Phyllis, Liu, Stephanie N., Gosselin, Nathalie, Sauve, Zacharie, Marchand, Mathilde, Lin, Alyse, Herraez‐Baranda, Luis, Zanghi, James, Shearer‐Kang, Esther, Liu, Xiaoyan, Wu, Benjamin, Chanu, Pascal
Format:	Journal Article
Language:	English
Published:	United States John Wiley & Sons, Inc 01.04.2025 John Wiley and Sons Inc Wiley
Subjects:	Abdomen Administration, Intravenous Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - pharmacokinetics Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Carcinoma, Non-Small-Cell Lung - drug therapy Cell death Dose-Response Relationship, Drug Drug development Drug dosages Female Humans Injections, Subcutaneous Lung cancer Lung Neoplasms - drug therapy Male Metastasis Middle Aged Models, Biological Patients Pharmacokinetics Population
ISSN:	2163-8306, 2163-8306
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!